source
- Novartis and Novo Nordisk see back-to-back cardiovascular trial failures, raising doubts for the fieldNovartis announced that its experimental heart‑protective therapy, pelacarsen, did not meet its primary endpoints in a seven‑year study designed to cut heart attacks and strokes by lowering lipopro…
- Cancer drug shortages persist, hampering patient care and highlighting lasting impacts of platinum chemotherapyThe STAT+ newsletter reports that cancer treatment centers continue to struggle with ongoing shortages of key oncology drugs, forcing clinicians to alter or delay therapy for patients. These short…